ArticleTranslational oncology2026
Lactylation profiling reveals novel biomarkers and immune interactions in pancreatic cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer, known for its aggressive nature and poor prognosis, often eludes early detection and effective treatment. This study investigates the underexplored terrain of protein lactylation in pancreatic cancer to identify potential biomarkers and understand its immunological implications. Proteomic and transcriptomic analyses were conducted to profile lactylation changes, identifying 11 upregulated and 1 downregulated lactylation-related proteins. Intersection analysis between proteomics and transcriptomics highlighted four key genes (COQ9, GAA, LYST and TP53) with consistent expression trends, suggesting their central role in the lactylation pathway within pancreatic cancer. ROC curve analysis underscored the diagnostic potential of GAA and LYST, with AUCs over 0.9. Further, ssGSEA revealed significant correlations between these core genes and various immune cells, indicating an immune-modulatory role. Notably, most core lactylation-related genes were positively associated with immune checkpoint molecules, barring COQ9. GSEA of gene expression groups delineated three conserved upregulated KEGG pathways, with additional REACTOME pathway analysis uncovering 68 conserved pathways. These findings highlight lactylation's involvement in pancreatic cancer progression and its possible exploitation for diagnostic and therapeutic advancements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.